Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
Introduction. Insulin is the most effective hypoglycemic agent currently used in the clinical practice. Compared with recombinant human insulin, insulin lispro have a blood glucose profile that is much closer to physiological. The clinical trials program of insulin bioassays includes pharmacology st...
Saved in:
| Main Authors: | A. Yu. Mayorov, I. A. Fedotov, R. V. Drai, O. I. Avdeeva, I. E. Makarenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2020-05-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters
by: Alexander Y. Mayorov, et al.
Published: (2018-12-01) -
Pharmacokinetics and pharmacodynamics of insulin lispro 25 versus the original preparation (Humalog®25) in Chinese healthy male volunteers
by: Mingxue Zhu, et al.
Published: (2025-02-01) -
Expression of CD14<sup>+</sup>CD282<sup>+</sup>, CD14<sup>+</sup>CD284<sup>+</sup>, CD14<sup>+</sup>HLA-DR<sup>+</sup>, CD14<sup>+</sup>CD11b<sup>+</sup> receptors and sIgA level in premature infants with <i>K. pneumoniae</i>
by: G. N. Chistyakova, et al.
Published: (2024-09-01) -
Diagnostically significant changes in subsets CD11b<sup>+</sup>CD64<sup>-</sup>CD32<sup>+</sup>CD16<sup>+</sup>, CD11b<sup>+</sup>CD64<sup>+</sup>CD32<sup>+</sup>CD16<sup>+</sup> neutrophilic granulocytes of immunocompromised women with chronic infectious and inflammatory diseases of the genital tract of various etiologies
by: S. V. Kovaleva, et al.
Published: (2023-06-01) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
by: Alexander Y. Mayorov, et al.
Published: (2020-12-01)